Recent Finacing
Recent Raise
RASRx develops an oral, mutation-independent, systems-biology therapy for Duchenne muscular dystrophy—licensed from USC—showing improved muscle strength, regeneration, and reduced inflammation and fibrosis in mdx mice.
Focus Areas
Recent Investors
Funding round
Investor